- Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
- Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
- Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
- Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
- Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
- Gain Therapeutics Announces Proposed Public Offering
- Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
- Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
- Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
- Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.08 |
---|---|
High | 1.08 |
Low | 1.02 |
Bid | 1.02 |
Offer | 1.03 |
Previous close | 1.08 |
Average volume | 223.63k |
---|---|
Shares outstanding | 18.05m |
Free float | 16.83m |
P/E (TTM) | -- |
Market cap | 19.50m USD |
EPS (TTM) | -1.53 USD |
Data delayed at least 15 minutes, as of Jul 25 2024 18:08 BST.
More ▼